Asset / Drug

Losartan Potassium

Drug and asset intelligence for Losartan Potassium with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 3
Stage: Development stage unavailable

Sponsor company

Micro Labs →

Recent signals(1)

StrategyJune 21, 2026

Lupin's ANDA078232 for Losartan Potassium Receives AP Status from FDA

Lupin Ltd. has received an Abbreviated New Drug Application (ANDA) approval status for Losartan Potassium.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

Lupin — Losartan Potassium

Monitor the launch timeline and market uptake of Lupin's Losartan Potassium product.

June 21, 2026 · N/A

Topline Data

Strides Pharma — Losartan Potassium

Monitor the launch timeline and market entry strategies of Strides Pharma for Losartan Potassium.

June 21, 2026 · N/A

Topline Data

Micro Labs — Losartan Potassium

Monitor for the final approval and market entry date, as well as any potential responses from competitors.

June 7, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Antihypertensive →

Cardiovascular →

Cardiovascular · Antihypertensive →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.